SOShinji Okabayashi

Shinji Okabayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinji Okabayashi has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Forecasting the Epidemiology of Inflammatory Bowel Disease in Brazil: A Temporal Evolution from 2012 to 2035

    by Abel Botelho Quaresma, Eduard Brunet-Mas, Stephanie B. Coward, Aderson O.M.C. Damiao, Claudio S.R. Coy, Julia Gorospe, Adriano A. F. Hino, Lindsay Hracs, Daniela Oliveira Magro, Remo Panaccione, et al.

    Background & Aims: Brazil is undergoing a rapid epidemiologic transition in inflammatory bowel disease (IBD). We aimed to characterize the temporal evolution of IBD in Brazil from 2012 to 2025 and forecast its burden through 2035, positioning the country within a global four-stage model.Methods: This nationwide, population-based study utilized the DATASUS database via the TT Disease Explorer platform. We identified individuals with Crohn’s Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassifiable (IBD-U) using validated ICD-10 codes from the public healthcare system. Temporal trends (Annual Average Percent Changes: AAPCs) and autoregressive integrated moving average (ARIMA) modeling was used to forecast incidence and prevalence.Results: A total of 337,539 IBD patients were identified. Between 2012 and 2025, IBD prevalence rose from 29·85 to 158·18 per 100,000 inhabitants and IBD incidence rose from 9·35 to 12·34 per 100,000 inhabitants. The UC:CD prevalence ratio increased from 1·53:1 to 2·1:1. Hotspots were concentrated in the South and Southeast regions. ARIMA models forecast that IBD prevalence will reach 264·4 per 100,000, while incidence is forecasted to rise to 22·72 per 100,000 by 2035.Conclusions: The incidence and prevalence in Brazil are rising significantly. By 2035, this escalating burden will necessitate a structural shift in the public healthcare systems toward longitudinal models of chronic care management.

  • Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study

    by Takahito Katano, Shinji Okabayashi, Hajime Yamazaki, Mao Matsubayashi, Kanade Serizawa, Masatoshi Nakashima, Motoki Kaneko, Katsuyoshi Matsuoka, Ryota Ogihara, Hiroki Kiyohara, et al.

    Background & Aims: Acute severe ulcerative colitis (ASUC) refractory to intravenous corticosteroids (IVCS) is a major clinical challenge with limited rescue therapy options. Although tacrolimus has been proposed as a potential rescue therapy, its effectiveness and safety compared with infliximab, widely used in this setting, remain unclear. Methods: A multicenter retrospective cohort study was conducted across 34 Japanese institutions, including hospitalized patients with IVCS-refractory ASUC who received infliximab or tacrolimus as rescue therapy between January 2014 and March 2023. The primary outcome was clinical remission at day 14, using two-item patient-reported outcome scoring. Secondary outcomes included clinical response at day 3 and 7, colectomy, and adverse events within 56 days. A modified Poisson regression model was used for analysis. Results: Among 300 patients (infliximab, n = 113; tacrolimus, n = 187), clinical remission at day 14 occurred in 41.6% and 33.7%, respectively, with no difference (adjusted risk ratio [RR] 0.87 [95% CI: 0.65, 1.17]). Clinical response at day 3 was lower with tacrolimus (infliximab 42.5% vs tacrolimus 24.1%; adjusted RR 0.58 [95% CI: 0.42, 0.80]) but did not differ at day 7 (infliximab 63.7% vs tacrolimus 51.9%; adjusted RR 0.83 [95% CI: 0.69, 1.01]). No difference in colectomy within 56 days was observed, although rates were higher in the tacrolimus (13.3% vs 20.3%; adjusted RR 1.58 [95% CI: 0.93, 2.67]). Adverse events were similar between groups (infliximab 8.8% vs tacrolimus 7.5%; adjusted RR 0.77 [95% CI: 0.37, 1.57]). Conclusions: Tacrolimus demonstrated comparable effectiveness and safety to infliximab as rescue therapy for IVCS-refractory ASUC, although early response was slower.

  • Top Cited Papers
    Open Access

    Global evolution of inflammatory bowel disease across epidemiologic stages

    by Lindsay Hracs, Joseph W. Windsor, Julia Gorospe, Michael Cummings, Stephanie Coward, Michael J. Buie, Joshua Quan, Quinn Goddard, Léa Caplan, Ante Markovinović, et al.

    During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.


  • Tu1506: CATEGORIZING THE RISK OF STEROID DEPENDENCE AFTER INITIAL STEROID THERAPY IN ULCERATIVE COLITIS: A NEW ANALYSIS WITH ARTIFICIAL NEURAL NETWORK

    by Yusuke Miyatani, Taku Kobayashi, Shinji Okabayashi, Endo Toshiyuki, Kunio Asonuma, Tomoe Tashiro, Aya Hojo, Hiromu Morikubo, Shintaro Sagami, Masaru Nakano, et al.

  • Editorial: is older‐onset ulcerative colitis more severe or less aggressively managed? Authorsʼ reply

    by Shinji Okabayashi, Hajime Yamazaki, Katsuyoshi Matsuoka, Yosuke Yamamoto, Taku Kobayashi


  • Open Access

    Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

    by Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, et al.

    The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis. Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day). The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group. Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype.